[go: up one dir, main page]

WO2014051532A1 - Pharmaceutical tablet formulations comprising cefdinir - Google Patents

Pharmaceutical tablet formulations comprising cefdinir Download PDF

Info

Publication number
WO2014051532A1
WO2014051532A1 PCT/TR2013/000302 TR2013000302W WO2014051532A1 WO 2014051532 A1 WO2014051532 A1 WO 2014051532A1 TR 2013000302 W TR2013000302 W TR 2013000302W WO 2014051532 A1 WO2014051532 A1 WO 2014051532A1
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
cellulose
polymer
formulation according
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2013/000302
Other languages
French (fr)
Inventor
Mahmut BILGIÇ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014051532A1 publication Critical patent/WO2014051532A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to the pharmaceutical formulations comprising cefdinir for use in the treatment of many diseases caused by gram positive and gram negative bacteria.
  • Cefdinir shown by the Formula I below, was first disclosed in the application no. BE897864. In said document, it is mentioned that cefdinir is effective for use in the treatment of many diseases caused by gram positive and gram negative bacteria.
  • Cefdinir is available in the market in capsule and suspension forms. It is necessary to orally administer the antibiotic drugs such as cefdinir, which are used for the treatment of the microbial infections, more than one time throughout the duration of the treatment. Although the oral administration of the drug is the most preferred route for the drug therapy, the antibiotic drugs with low bioavailability such as cefdinir are known to be quite inefficient for the use via oral route. In addition, a considerably high antibiotic plasma concentration is required in order for the antibiotics to reach the minimum inhibitory concentration (MIC) value against the bacteria. Accordingly, in order for the antibiotic drugs such as cefdinir to provide the desired therapeutic activity, they are required to be administered several times a day via the oral route. However, the necessity to administer the drugs suitable for oral use, containing cefdinir, more than one time a day leads to the inconvenience for the patient as well as the reduction of the patient compliance and thus the achievement of a lower therapeutic effect.
  • the antibiotic drugs suitable for oral use, containing cefdinir more than one time
  • the pharmaceutical formulations suitable for oral administration said formulations enabling the release of cefdinir in a controlled manner in the blood such that the active ingredient of cefdinir achieves the effective level in the blood for a long time.
  • the inventors have surprisingly found that in case the pharmaceutical formulations comprising cefdinir are formulated in the form of modified release tablets and in case they comprise, at a ratio of 0,5-15%, a cellulose based polymer providing controlled release, the active ingredient of cefdinir reaches a constant blood level and therefore, the frequency of drug administration is reduced and the patient compliance and the therapeutic efficacy are increased.
  • the present invention relates to the pharmaceutical formulations comprising cefdinir and the preparation of such formulations.
  • the inventors have surprisingly found that in case the pharmaceutical formulations comprising cefdinir are prepared in the form of modified release tablets and in case they comprise, at a ratio of 0,5-1 %, a cellulose-based polymer providing controlled release, the active ingredient of cefdinir has a constant blood level and therefore, the frequency of drug administration is reduced and the patient compliance and the therapeutic efficacy are increased.
  • the first feature of the present invention is the cefdinir formulations, which are formulated in modified release table form and which contain a cellulose-based controlled release polymer at a ratio of 0,5- 15%.
  • Cefdinir contained in the pharmaceutical formulations according to the invention, may be present in the form of solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination of the same.
  • the formulations according to the invention preferably comprise the cellulose-based controlled release polymer at a ratio of 1-10%, more preferably 2-8%.
  • the cellulose-based polymer providing controlled release contained by the formulations according to the present invention, may be selected from a group consisting of carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hypromellose or the combinations thereof.
  • hydroxypropyl methyl cellulose may be used as the cellulose-based polymer providing controlled release.
  • the pharmaceutical formulations according to the invention may comprise hydroxypropyl methyl cellulose at a ratio of 2-8%.
  • the formulation according to the invention may, in addition to cefdinir and the polymer providing controlled release, comprise at least one pharmaceutically acceptable auxiliary agent selected from a diluting agent, lubricating agent and film coating agent.
  • the diluting agent contained by the formulation according to the invention may be selected from a group consisting of D-mannitol, xylitol, microcrystalline cellulose, crospovidone, dibasic calcium phosphate anhydrous, lactose, starch, maltose, dextrin, maltodextrin, magnesium carbonate, talc and the combinations thereof.
  • Cefdinir is known to have a low solubility in the body and therefore a low bioavailability.
  • the inventors have observed in the studies they conducted that in the formulations prepared so that the ratio of the weight of the cellulose-based polymer providing controlled release.'the weight of the diluting agent will be between 3 : 1 and 1 : 10, preferably between 1 : 1 and 1 :8, the bioavailability of cefdinir increases, and therefore the effective drug level in the blood is more easily achieved and the therapeutic efficacy increases.
  • the ratio of the weight of the cellulose-based polymer providing controlled release :the weight of the diluting agent is between 3:1 and 1 :10, preferably between 1 :1 and 1 :8.
  • the lubricating agent contained by the formulations according to the invention may be selected from a group consisting of calcium stearate, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
  • the film coating agent contained by the formulations according to the invention may be selected from a group consisting of titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin or the combinations thereof.
  • the film coating agent commercially available under the trademark Opadry Yellow® may be used.
  • the pharmaceutical formulation according to the invention may comprise 0,5-95% cefdinir, 0,5-50% diluting agent, 0,5-15% controlled release polymer and 0,1-5% lubricating agent based on the total weight of the unit dose amount.
  • the pharmaceutical formulation according to the invention may be obtained by a method comprising the steps of compacting the active ingredient cefdinir and the diluting agent, adding the polymer providing the controlled release to the compacted powder and mixing the same, adding the lubricating agent to this mixture and mixing again, pressing the final mixture in the form of a tablet and coating the pressed tablets with a coating solution comprising the coating agent.
  • Another problem observed in the formulations according to the invention is the disintegration and fragmentation of the tablet during or after the pressing of the tablet. This problem causes the loss of material after the manufacture as well as the damage to the integrity of the tablet during the use, thereby leading the efficacy of the treatment to be adversely affected.
  • the inventors have observed that in case the active ingredient and the diluting agent are compacted prior to being mixed with the controlled release polymer in order to prevent the disintegration of the tablet during or after the pressing of the same, no disintegration or fragmentation occurs in the tablet during and after the pressing of the same. Accordingly, a feature of the method employed for the preparation of the formulations according to the present invention is that cefdinir and the diluting agent are compacted prior to being mixed with the polymer that provides the controlled release.
  • Another problem encountered during the manufacture of the pharmaceutical formulation according to the present invention is the agglomeration of the powder formulation.
  • the inventors have observed that the formation of agglomerates is prevented by adding the polymer that provides the controlled release in the formulation according to the invention in two steps.
  • Another feature of the manufacturing method employed for the preparation of the formulations according to the present invention is that the polymer that provides the controlled release is added in two steps.
  • Another problem encountered during the manufacture of the formulations according to the present invention is the adhesion of the primary mixture in powder form to the components of the pressing machine during the pressing of the tablet, thereby leading to the loss of product.
  • said problem has been solved owing to the ratio of the controlled 302
  • release polymer added in the first step to the controlled release polymer added in the second step varying between 10:1 and 1:1 in the manufacturing method.
  • the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 10:1 and 1 :1 in the manufacturing method employed for preparing said formulation.
  • the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 7:1 and 2: 1 in the manufacturing method employed for preparing the formulations according to the present invention.
  • the method for manufacturing the pharmaceutical formulations according to the invention comprises the steps of
  • the pharmaceutical formulation according to the invention may be used in the prevention and treatment of many diseases caused by the gram positive and gram negative bacteria.
  • Example 1 Formulation and process for preparing a cefdinir tablet
  • cefdinir is compacted with the polymer providing the controlled release, the diluting agent is added and stirred in a mixer. The lubricating agent is added to this mixture and mixed again. The polymer providing the controlled release is added to the mixture obtained and the powder mixture thus obtained is pressed in tablet form. The pressed tablet is coated with a coating solution containing the film coating agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Description

DESCRIPTION
PHARMACEUTICAL TABLET FORMULATIONS COMPRISING CEFDINIR
The present invention relates to the pharmaceutical formulations comprising cefdinir for use in the treatment of many diseases caused by gram positive and gram negative bacteria. Cefdinir, shown by the Formula I below, was first disclosed in the application no. BE897864. In said document, it is mentioned that cefdinir is effective for use in the treatment of many diseases caused by gram positive and gram negative bacteria.
Figure imgf000002_0001
Formula I
Cefdinir is available in the market in capsule and suspension forms. It is necessary to orally administer the antibiotic drugs such as cefdinir, which are used for the treatment of the microbial infections, more than one time throughout the duration of the treatment. Although the oral administration of the drug is the most preferred route for the drug therapy, the antibiotic drugs with low bioavailability such as cefdinir are known to be quite inefficient for the use via oral route. In addition, a considerably high antibiotic plasma concentration is required in order for the antibiotics to reach the minimum inhibitory concentration (MIC) value against the bacteria. Accordingly, in order for the antibiotic drugs such as cefdinir to provide the desired therapeutic activity, they are required to be administered several times a day via the oral route. However, the necessity to administer the drugs suitable for oral use, containing cefdinir, more than one time a day leads to the inconvenience for the patient as well as the reduction of the patient compliance and thus the achievement of a lower therapeutic effect.
Accordingly, there is a need for the development of the pharmaceutical formulations suitable for oral administration, said formulations enabling the release of cefdinir in a controlled manner in the blood such that the active ingredient of cefdinir achieves the effective level in the blood for a long time. The inventors have surprisingly found that in case the pharmaceutical formulations comprising cefdinir are formulated in the form of modified release tablets and in case they comprise, at a ratio of 0,5-15%, a cellulose based polymer providing controlled release, the active ingredient of cefdinir reaches a constant blood level and therefore, the frequency of drug administration is reduced and the patient compliance and the therapeutic efficacy are increased.
Description of the Invention
The present invention relates to the pharmaceutical formulations comprising cefdinir and the preparation of such formulations. The inventors have surprisingly found that in case the pharmaceutical formulations comprising cefdinir are prepared in the form of modified release tablets and in case they comprise, at a ratio of 0,5-1 %, a cellulose-based polymer providing controlled release, the active ingredient of cefdinir has a constant blood level and therefore, the frequency of drug administration is reduced and the patient compliance and the therapeutic efficacy are increased. As a result, the first feature of the present invention is the cefdinir formulations, which are formulated in modified release table form and which contain a cellulose-based controlled release polymer at a ratio of 0,5- 15%.
Cefdinir, contained in the pharmaceutical formulations according to the invention, may be present in the form of solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination of the same.
The formulations according to the invention preferably comprise the cellulose-based controlled release polymer at a ratio of 1-10%, more preferably 2-8%.
The cellulose-based polymer providing controlled release, contained by the formulations according to the present invention, may be selected from a group consisting of carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hypromellose or the combinations thereof.
In the pharmaceutical formulations according to the present invention, hydroxypropyl methyl cellulose may be used as the cellulose-based polymer providing controlled release. The pharmaceutical formulations according to the invention may comprise hydroxypropyl methyl cellulose at a ratio of 2-8%.
The formulation according to the invention, may, in addition to cefdinir and the polymer providing controlled release, comprise at least one pharmaceutically acceptable auxiliary agent selected from a diluting agent, lubricating agent and film coating agent.
The diluting agent contained by the formulation according to the invention may be selected from a group consisting of D-mannitol, xylitol, microcrystalline cellulose, crospovidone, dibasic calcium phosphate anhydrous, lactose, starch, maltose, dextrin, maltodextrin, magnesium carbonate, talc and the combinations thereof. Cefdinir is known to have a low solubility in the body and therefore a low bioavailability. The inventors have observed in the studies they conducted that in the formulations prepared so that the ratio of the weight of the cellulose-based polymer providing controlled release.'the weight of the diluting agent will be between 3 : 1 and 1 : 10, preferably between 1 : 1 and 1 :8, the bioavailability of cefdinir increases, and therefore the effective drug level in the blood is more easily achieved and the therapeutic efficacy increases.
Accordingly, another feature of the present invention is that the ratio of the weight of the cellulose-based polymer providing controlled release :the weight of the diluting agent is between 3:1 and 1 :10, preferably between 1 :1 and 1 :8.
The lubricating agent contained by the formulations according to the invention may be selected from a group consisting of calcium stearate, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
The film coating agent contained by the formulations according to the invention may be selected from a group consisting of titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin or the combinations thereof. For example, the film coating agent commercially available under the trademark Opadry Yellow® may be used.
The pharmaceutical formulation according to the invention may comprise 0,5-95% cefdinir, 0,5-50% diluting agent, 0,5-15% controlled release polymer and 0,1-5% lubricating agent based on the total weight of the unit dose amount. The pharmaceutical formulation according to the invention may be obtained by a method comprising the steps of compacting the active ingredient cefdinir and the diluting agent, adding the polymer providing the controlled release to the compacted powder and mixing the same, adding the lubricating agent to this mixture and mixing again, pressing the final mixture in the form of a tablet and coating the pressed tablets with a coating solution comprising the coating agent.
Another problem observed in the formulations according to the invention is the disintegration and fragmentation of the tablet during or after the pressing of the tablet. This problem causes the loss of material after the manufacture as well as the damage to the integrity of the tablet during the use, thereby leading the efficacy of the treatment to be adversely affected. During the studies, the inventors have observed that in case the active ingredient and the diluting agent are compacted prior to being mixed with the controlled release polymer in order to prevent the disintegration of the tablet during or after the pressing of the same, no disintegration or fragmentation occurs in the tablet during and after the pressing of the same. Accordingly, a feature of the method employed for the preparation of the formulations according to the present invention is that cefdinir and the diluting agent are compacted prior to being mixed with the polymer that provides the controlled release.
Another problem encountered during the manufacture of the pharmaceutical formulation according to the present invention is the agglomeration of the powder formulation. In the studies conducted with a view to eliminate this problem, the inventors have observed that the formation of agglomerates is prevented by adding the polymer that provides the controlled release in the formulation according to the invention in two steps.
Accordingly, another feature of the manufacturing method employed for the preparation of the formulations according to the present invention is that the polymer that provides the controlled release is added in two steps.
Another problem encountered during the manufacture of the formulations according to the present invention is the adhesion of the primary mixture in powder form to the components of the pressing machine during the pressing of the tablet, thereby leading to the loss of product. In the studies conducted in order to improve the manufacturing method for the formulation according to the invention, said problem has been solved owing to the ratio of the controlled 302
release polymer added in the first step to the controlled release polymer added in the second step varying between 10:1 and 1:1 in the manufacturing method.
Accordingly, another feature of the present invention is that the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 10:1 and 1 :1 in the manufacturing method employed for preparing said formulation.
According to another aspect, the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 7:1 and 2: 1 in the manufacturing method employed for preparing the formulations according to the present invention. According to another aspect, the method for manufacturing the pharmaceutical formulations according to the invention comprises the steps of
• compacting the active ingredient cefdinir and the diluting agent,
• adding the polymer providing the controlled release to the compacted powder and mixing the same,
· adding the lubricating agent to the mixture formed and mixing again,
• adding the polymer providing the controlled release to this mixture,
• pressing the mixture in the form of a tablet,
• coating the pressed tablets with a coating solution comprising the coating agent
The pharmaceutical formulation according to the invention may be used in the prevention and treatment of many diseases caused by the gram positive and gram negative bacteria.
Example 1: Formulation and process for preparing a cefdinir tablet
Figure imgf000006_0001
Lubricating agent 3%
Film coating agent 2%
In order to obtain the formulation to be used in the present invention, cefdinir is compacted with the polymer providing the controlled release, the diluting agent is added and stirred in a mixer. The lubricating agent is added to this mixture and mixed again. The polymer providing the controlled release is added to the mixture obtained and the powder mixture thus obtained is pressed in tablet form. The pressed tablet is coated with a coating solution containing the film coating agent.

Claims

1. Pharmaceutical formulations comprising cefdinir characterized in that they are formulated in modified release tablet form and they contain a cellulose-based controlled release polymer at a ratio of 0,5- 15%.
2. A pharmaceutical formulation according to Claim 1 characterized in that it comprises a cellulose-based controlled release polymer at a ratio of 1-10%.
3. A pharmaceutical formulation according to Claims 1-2 characterized in that it comprises a cellulose-based controlled release polymer at a ratio of 2-8%.
4. A pharmaceutical formulation according to any one of the preceding claims characterized in that the cellulose-based polymer providing controlled release, contained by said formulation, is selected from a group consisting of carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hypromellose or the combinations thereof.
5. A pharmaceutical formulation according to Claim 4 characterized in that the cellulose- based polymer providing controlled release, contained by the formulation according to the invention, is hydroxypropyl methyl cellulose.
6. A pharmaceutical formulation according to any one of the preceding claims characterized in that it comprises hydroxypropyl methyl cellulose at a ratio of 2-8%.
7. A pharmaceutical formulation according to any one of the preceding claims characterized in that it comprises, in addition to cefdinir and the polymer providing controlled release, a diluting agent, lubricating agent and film coating agent.
8. A pharmaceutical formulation according to any one of the preceding claims characterized in that the diluting agent contained by the formulation is selected from a group consisting of D-mannitol, xylitol, microcrystalline cellulose, crospovidone, dibasic calcium phosphate anhydrous, lactose, starch, maltose, dextrin, maltodextrin, magnesium carbonate, talc and the combinations thereof.
9. A pharmaceutical formulation according to any one of the preceding claims characterized in that the ratio of the weight of the cellulose-based polymer providing controlled release:the weight of the diluting agent is between 3 : 1 and 1 : 10.
10. A pharmaceutical formulation according to Claim 9 characterized in that the ratio of the weight of the cellulose-based polymer providing controlled release:the weight of the diluting agent is between 1 : 1 and 1 :8.
11. A pharmaceutical formulation according to any one of the preceding claims characterized in that it comprises 0,5-95% cefdinir, 0,5-50% diluting agent, 0,5-15% controlled release polymer and 0,1-5% lubricating agent based on the total weight of the unit dose amount.
12. A method for the manufacture of a pharmaceutical formulation according to any one of the preceding claims characterized in that the pharmaceutical formulation according to the invention is obtained by a method comprising the steps of compacting cefdinir and the diluting agent, adding the polymer providing the controlled release to the compacted powder and mixing the same, adding the lubricating agent to this mixture and mixing again, pressing the final mixture in the form of a tablet and coating the pressed tablets with a coating solution comprising the coating agent.
13. A manufacturing method according Claim 12 characterized in that cefdinir and the diluting agent are compacted prior to being mixed with the polymer that provides the controlled release.
14. A manufacturing method according Claims 12-13 characterized in that the polymer providing the controlled release is added in two steps.
15. A manufacturing method according Claim 14 characterized in that the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 10: 1 and 1 :1.
16. A manufacturing method according Claim 15 characterized in that the ratio of the controlled release polymer added in the first step to the controlled release polymer added in the second step is between 7: 1 and 2: 1.
17. A manufacturing method according Claims 12-16 characterized in that it comprises the process steps of
• compacting the active ingredient cefdinir and the diluting agent,
· adding the polymer providing the controlled release to the compacted powder and mixing the same,
• adding the lubricating agent to the mixture formed and mixing again,
• adding the polymer providing the controlled release to this mixture,
• pressing the mixture in the form of a tablet,
· coating the pressed tablets with a coating solution comprising the coating agent.
PCT/TR2013/000302 2012-09-28 2013-09-30 Pharmaceutical tablet formulations comprising cefdinir Ceased WO2014051532A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201211056 2012-09-28
TR2012/11056 2012-09-28

Publications (1)

Publication Number Publication Date
WO2014051532A1 true WO2014051532A1 (en) 2014-04-03

Family

ID=49753447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000302 Ceased WO2014051532A1 (en) 2012-09-28 2013-09-30 Pharmaceutical tablet formulations comprising cefdinir

Country Status (1)

Country Link
WO (1) WO2014051532A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890359A1 (en) * 1996-02-29 1999-01-13 Fujisawa Pharmaceutical Co., Ltd. Tablets containing beta-lactam antibiotic and process for producing the same
CN101002745A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of cefdinir
WO2007125541A1 (en) * 2006-05-01 2007-11-08 Lupin Limited Pharmaceutical compositions of cefdinir
WO2012060787A1 (en) * 2010-11-05 2012-05-10 Mahmut Bilgic Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890359A1 (en) * 1996-02-29 1999-01-13 Fujisawa Pharmaceutical Co., Ltd. Tablets containing beta-lactam antibiotic and process for producing the same
CN101002745A (en) * 2005-09-26 2007-07-25 刘凤鸣 Slow release preparation of cefdinir
WO2007125541A1 (en) * 2006-05-01 2007-11-08 Lupin Limited Pharmaceutical compositions of cefdinir
WO2012060787A1 (en) * 2010-11-05 2012-05-10 Mahmut Bilgic Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHERALA RAMAKRISHNA ET AL: "FORMULATION AND EVALUATION OF CEFDINIR ONCE DAILY SUSTAINED RELEASE MATRIX TABLETS", PHARMANEST - AN INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACEUTICAL SCIENCES, August 2011 (2011-08-01), pages 403 - 416, XP055097665, Retrieved from the Internet <URL:http://www.pharmanest.net/pdf.php?fileid=1342177789.pdf> [retrieved on 20140121] *

Similar Documents

Publication Publication Date Title
EP0749308B1 (en) Film coated tablet of paracetamol and domperidone
US20100151034A1 (en) Granular pharmaceutical composition of atorvastatin for oral administration
JP2019505525A (en) Pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof
US20080069879A1 (en) Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
EP2187874A2 (en) Sustained release compositions of trimetazidine and process for preparation thereof
EA025389B1 (en) Pharmaceutical formulations
EP3911304A1 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
JP2019526591A (en) Pharmaceutical composition comprising rosuvastatin and ezetimibe and method for preparing the same
EP3013327A1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
WO2010098482A1 (en) Stable capsule preparation and method for producing same
JP5381978B2 (en) Amide derivative-containing pharmaceutical composition
CN108420798B (en) Quick-release medicinal preparation of anticoagulant and preparation method thereof
KR101697773B1 (en) Modified release composition comprising doxofylline
US20110217369A1 (en) Fenofibrate compositions
KR101497354B1 (en) Slow release pharmaceutical composition having Eperisone as active ingredient
US20100272794A1 (en) Pharmaceutical composition of memantine
WO2014051532A1 (en) Pharmaceutical tablet formulations comprising cefdinir
JP7150862B2 (en) Composition of aminopyran derivatives
KR102231289B1 (en) High Content Chondroitin Sulfate Pharmaceutical Formulation and Manufacturing Method Thereof
EP3360542A1 (en) Tablet forms of vilazodone hydrochloride
EP2848260A1 (en) Novel formulations of thiocolchicoside
EP3900708A1 (en) Extended-release medical composition containing zaltoprofen
EP2848259B1 (en) Sustained release pharmaceutical formulations of Thiocolchicoside
WO2016135740A1 (en) Process for preparing stable oral compositions of everolimus
JP2022136252A (en) Oral formulation containing ezetimibe and its manufacturing method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13802747

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13802747

Country of ref document: EP

Kind code of ref document: A1